Act-777991

Phase 2

Idorsia Pharmaceuticals Ltd.

Act-777991 is one of 4 therapeutic programs targeting Non-segmental Vitiligo. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Non-Segmental VitiligoNot yet recruiting

Non-Segmental VitiligoPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Non-Segmental Vitiligo

#DrugCompanyPhaseTrials

Opzelura

Pfizer

Phase 3

1 2

MK-6194

Merck & Co.

Phase 2

1 3

GIA632

Novartis

Phase 2

1 4

Act-777991

Idorsia Pharmaceuticals Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Non-Segmental Vitiligo

NCT07667569

Clinical

Trials by Indication[1]

Non-segmental Vitiligo1 trial

A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo

Not yet recruiting· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 2·NCT07667569·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Act-777991. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Act-777991. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Idorsia Pharmaceuticals Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Idorsia Pharmaceuticals Ltd.

Act-777991

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Non-segmental Vitiligo1 trial

References

Drug Info

Quick Facts

Related News